A study led by Yale Cancer Center found that more men received a prostate-specific antigen (PSA) test to detect prostate cancer following revisions to the recommendation by the U.S. Preventative Services Task Force on screening.
FDA approved the anti-PD-1 therapy Keytruda (pembrolizumab) for the adjuvant treatment of patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Mark McLaughlin—a researcher with the West Virginia University Cancer Institute and Modulation Therapeutics Inc.—and his colleagues have received FDA approval to begin human trials of a new drug called MTI-201, which treats uveal melanoma after the cancer has traveled to another part of the body.
Ribonexus (previously Aglaia Therapeutics) and French pharmaceutical group Pierre Fabre signed an exclusive license agreement on a series of Pierre Fabre-patented small molecules targeting the eukaryotic translation initiation factor 4A (eIF4A). This target is highly expressed in a variety of solid and hematologic cancers, including melanoma, and associated with resistance to many current therapies.
President Biden has been describing the Advanced Research Projects Agency for Health (ARPA-H), a DARPA-like biomedical research agency, as the centerpiece of his effort to “end cancer as we know it.”
Robert Califf has been nominated by President Joe Biden to serve as the next commissioner of FDA, replacing acting commissioner Janet Woodcock.
Ralph J. DeBerardinis, Sun Hur, and Charles Swanton received the Memorial Sloan Kettering Cancer Center’s 2021 Paul Marks Prize for Cancer Research.
In Vino Vita, a Fox Chase Cancer Center fundraising event, raised over $1.5 million for cancer research, treatment, and prevention.
SEngine Precision Medicine and Dana-Farber Cancer Institute are collaborating to bring SEngine’s next-generation diagnostic PARIS test to adult and pediatric patients with primary or metastatic solid-tumor central nervous system cancers.
Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have partnered with Horizon Blue Cross Blue Shield of New Jersey to establish a collaborative pilot program providing home infusion cancer treatments to eligible patients.
